Scientists are rapidly focused on retatrutide, a innovative drug developed by Eli Lilly, as a potential step in weight management. Distinct from many earlier approaches, retatrutide is a double -action compound targeting equally GLP-1 and GIP, chemicals that impact hunger and blood glucose regulati